Literature DB >> 30276421

Effects of the second-generation "bath salt" cathinone alpha-pyrrolidinopropiophenone (α-PPP) on behavior and monoamine neurochemistry in male mice.

Azizi Ray1, Neha Milind Chitre1, Cedrick Maceo Daphney1, Bruce E Blough2, Clinton E Canal1, Kevin Sean Murnane3.   

Abstract

RATIONALE: Synthetic cathinones ("bath salts") are β-ketone analogs of amphetamines, yet few studies have examined their potential neurotoxic effects.
OBJECTIVE: In the current study, we assessed the persistent behavioral and neurochemical effects of exposure to the second-generation synthetic cathinone α-pyrrolidinopropiophenone (α-PPP).
METHODS: Male, Swiss-Webster mice were exposed to α-PPP (80 mg/kg) using a binge-like dosing regimen (QID, q2h). Behavior was assessed 4-5 days after the dosing regimen, and neurochemistry was assessed the following day. Behavior was studied using the elevated plus maze, Y-maze, and novel object recognition tests. Regional levels of dopamine, serotonin, norepinephrine, and the major dopamine metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) were determined in the prefrontal cortex and striatum using high-pressure liquid chromatography. Additional experiments assessed the time courses of the effects of α-PPP on locomotor activity and core temperature using telemetry.
RESULTS: Exposure to α-PPP significantly impaired performance in the Y-maze, decreased overall exploratory activity in the novel object recognition test, and resulted in regionally specific depletions in monoamine neurochemistry. In contrast, it had no significant effect on elevated plus maze performance or object discrimination in the novel object recognition test. The locomotor-stimulant effects of α-PPP were comparable to cocaine (30 mg/kg), and α-PPP (80 mg/kg) did not induce hyperthermia.
CONCLUSIONS: α-PPP exposure results in persistent changes in exploratory behavior, spatial working memory, and monoamine neurochemistry. This research highlights potential dangers of α-PPP, including potential neurotoxicity, and suggests that the mechanisms underlying the persistent untoward effects of the cathinones may be distinct from those of the amphetamines.

Entities:  

Keywords:  Alpha-ppp; Cathinone; Dopamine; Monoamine; Neurotoxicity; Y-maze

Mesh:

Substances:

Year:  2018        PMID: 30276421      PMCID: PMC6443494          DOI: 10.1007/s00213-018-5044-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  53 in total

Review 1.  The neurobiological basis of spontaneous alternation.

Authors:  Robert Lalonde
Journal:  Neurosci Biobehav Rev       Date:  2002-01       Impact factor: 8.989

Review 2.  Risk-taking behavior in adolescent mice: psychobiological determinants and early epigenetic influence.

Authors:  Giovanni Laviola; Simone Macrì; Sara Morley-Fletcher; Walter Adriani
Journal:  Neurosci Biobehav Rev       Date:  2003 Jan-Mar       Impact factor: 8.989

3.  Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety.

Authors:  Bríd Aine Nic Dhonnchadha; Michel Bourin; Martine Hascoët
Journal:  Behav Brain Res       Date:  2003-03-18       Impact factor: 3.332

4.  Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user.

Authors:  S J Kish; Y Furukawa; L Ang; S P Vorce; K S Kalasinsky
Journal:  Neurology       Date:  2000-07-25       Impact factor: 9.910

5.  Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons.

Authors:  L Reneman; J Booij; K de Bruin; J B Reitsma; F A de Wolff; W B Gunning; G J den Heeten; W van den Brink
Journal:  Lancet       Date:  2001-12-01       Impact factor: 79.321

6.  Enhanced release of norepinephrine in rat hippocampus during spontaneous alternation tests.

Authors:  D Men; R McCarty; P E Gold
Journal:  Neurobiol Learn Mem       Date:  1999-05       Impact factor: 2.877

7.  Behavioural changes in rats treated with a neurotoxic dose regimen of dextrorotatory amphetamine derivatives.

Authors:  J Timár; S Gyarmati; A Szabó; S Fürst
Journal:  Behav Pharmacol       Date:  2003-05       Impact factor: 2.293

8.  Long-term effects of p-chloroamphetamine and related drugs on central serotonergic mechanisms.

Authors:  E Sanders-Bush; J A Bushing; F Sulser
Journal:  J Pharmacol Exp Ther       Date:  1975-01       Impact factor: 4.030

9.  3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein.

Authors:  Xiaoying Wang; Michael H Baumann; Heng Xu; Richard B Rothman
Journal:  Synapse       Date:  2004-09-15       Impact factor: 2.562

10.  MDMA exposure alters cognitive and electrophysiological sensitivity to rapid tryptophan depletion in rhesus monkeys.

Authors:  Michael A Taffe; Salvador Huitrón-Resendiz; Richard Schroeder; Loren H Parsons; Steven J Henriksen; Lisa H Gold
Journal:  Pharmacol Biochem Behav       Date:  2003-08       Impact factor: 3.533

View more
  11 in total

1.  The cannabinoid receptor 2 agonist, β-caryophyllene, improves working memory and reduces circulating levels of specific proinflammatory cytokines in aged male mice.

Authors:  Lindsey Phillips Lindsey; Cedrick Maceo Daphney; Aboagyewaah Oppong-Damoah; Peter Nikolaevich Uchakin; Sarah E Abney; Olga N Uchakina; Richard Darien Khusial; Ayman Akil; Kevin Sean Murnane
Journal:  Behav Brain Res       Date:  2019-06-04       Impact factor: 3.332

Review 2.  Serotonin 2A receptors are a stress response system: implications for post-traumatic stress disorder.

Authors:  Kevin Sean Murnane
Journal:  Behav Pharmacol       Date:  2019-04       Impact factor: 2.293

3.  Docosahexaenoic acid protects motor function and increases dopamine synthesis in a rat model of Parkinson's disease via mechanisms associated with increased protein kinase activity in the striatum.

Authors:  Neha Milind Chitre; Bo Jarrett Wood; Azizi Ray; Nader H Moniri; Kevin Sean Murnane
Journal:  Neuropharmacology       Date:  2020-01-27       Impact factor: 5.250

4.  M100907 and BD 1047 attenuate the acute toxic effects of methamphetamine.

Authors:  Azizi Ray; Clinton E Canal; J Christopher Ehlen; Kenner C Rice; Kevin Sean Murnane
Journal:  Neurotoxicology       Date:  2019-06-01       Impact factor: 4.294

5.  The acute toxic and neurotoxic effects of 3,4-methylenedioxymethamphetamine are more pronounced in adolescent than adult mice.

Authors:  Neha Milind Chitre; Monique Simone Bagwell; Kevin Sean Murnane
Journal:  Behav Brain Res       Date:  2019-12-03       Impact factor: 3.332

6.  Effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on ethanol consumption and place conditioning in male mice.

Authors:  Aboagyewaah Oppong-Damoah; Kristen E Curry; Bruce E Blough; Kenner C Rice; Kevin S Murnane
Journal:  Psychopharmacology (Berl)       Date:  2019-07-15       Impact factor: 4.530

7.  The adrenergic receptor antagonist carvedilol interacts with serotonin 2A receptors both in vitro and in vivo.

Authors:  Kevin Sean Murnane; Osman F Guner; J Phillip Bowen; Kalyn M Rambacher; Nader H Moniri; Tyler J Murphy; Cedrick Maceo Daphney; Aboagyewaah Oppong-Damoah; Kenner C Rice
Journal:  Pharmacol Biochem Behav       Date:  2019-04-15       Impact factor: 3.533

8.  Quantifying the inverted U: A meta-analysis of prefrontal dopamine, D1 receptors, and working memory.

Authors:  Matthew A Weber; Mackenzie M Conlon; Hannah R Stutt; Linder Wendt; Patrick Ten Eyck; Nandakumar S Narayanan
Journal:  Behav Neurosci       Date:  2022-04-07       Impact factor: 2.154

9.  Nanoparticle encapsulation increases the brain penetrance and duration of action of intranasal oxytocin.

Authors:  Aboagyewaah Oppong-Damoah; Rokon Uz Zaman; Martin J D'Souza; Kevin Sean Murnane
Journal:  Horm Behav       Date:  2018-12-30       Impact factor: 3.587

10.  Reinforcing Effects of the Synthetic Cathinone α-Pyrrolidinopropiophenone (α-PPP) in a Repeated Extended Access Binge Paradigm.

Authors:  Erin K Nagy; Paula F Overby; M Foster Olive
Journal:  Front Psychiatry       Date:  2020-08-25       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.